David Bhatt

David Bhatt was central in the clinical development of dendritic cell-based cancer vaccines, contributing to the regulatory approval of sipuleucel-T as the first therapeutic cancer vaccine for castration-resistant prostate cancer. His research characterized the mechanisms by which autologous antigen-loaded dendritic cell vaccines activate T cell responses against prostate cancer. He contributed to the pivotal IMPACT trial demonstrating a survival benefit for sipuleucel-T in asymptomatic or minimally symptomatic castration-resistant prostate cancer. His work established proof-of-concept for therapeutic cancer vaccination.